Shionogi Receives Marketing, Manufacturing Approval Of Influenza Drug
Rapiacta, licensed from US-based BioCryst Pharmaceuticals, has been developed by Shionogi in Japan. Shionogi received approval for both single dose administration for adult uncomplicated seasonal influenza infection as
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.